N
Novartis AG (NVS)
NYQ – Real vaqt narxi. Valyuta: USD
148.18
-1.52 (-1.02%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
149.95
+1.77 (1.19%)
Bozordan keyin: Mar 27, 2026, 6:58 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
NYQ – Real vaqt narxi. Valyuta: USD
148.18
-1.52 (-1.02%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
149.95
+1.77 (1.19%)
Bozordan keyin: Mar 27, 2026, 6:58 PM EDT
Novartis AG Shveytsariyada va xalqaro miqyosda farmatsevtik dori vositalarini tadqiq etadi, ishlab chiqadi, ishlab chiqaradi, tarqatadi, sotadi va sotadi. Kompaniya ExSFrEF bilan simptomatik surunkali yurak etishmovchiligini davolash uchun angiotensin retseptorlari neprilizin inhibitori Entresto; blyashka psoriaz, psoriatik artrit, ankilozan spondilit va radiografik bo'lmagan o'q spondiloartritni davolash uchun Cosentyx; 4 va 6 siklin bog'langan kinazlar (CDK4/6) selektiv og'iz inhibitori Kisqali; immunitet trombotsitopeniyasi (ITP), trombotsitopeniya va og'ir aplastik anemiya (SAA) bilan og'rigan bemorlarni davolash uchun Promacta/Revolade; saratonning ma'lum turlari bilan og'rigan bemorlarni davolash uchun og'zaki kombinatsiyalangan terapiya Tafinlar+Mekinist; va mielofibroz, polisitemiya vera va o'tkir yoki surunkali graft-versus-host kasalligini (GvHD) davolash uchun Jakavi. Shuningdek, u surunkali va/yoki tezlashgan faza uchun filadelfiya xromosomasi-pozitiv surunkali miyeloid leykemiyani davolash uchun Tasigna; allergik astma va burun poliplari yoki burun poliplari bilan og'rigan og'ir surunkali rinosinusitni davolash uchun Xolair; isitma sindromlari, Still kasalligi va o'tkir podagra artritini davolash uchun Ilaris; prostata-spesifik membran antigen-pozitiv metastatik kastratsiyaga chidamli prostata saratonini davolash uchun Pluvicto; akromegaliya karsinoid o'smalari va boshqa turdagi funktsional gastrointestinal va oshqozon osti bezi neyroendokrin o'smalarini davolash uchun Sandostatin SC va Sandostatin LAR; spinal mushak atrofiyasining genetik asosiy sababini davolash uchun Zolgensma; Lucentis; LDL xolesterinini kamaytirish uchun Leqvio; Lutathera; Scemblix; va Fabhalta. Kompaniya kardiovaskulyar, buyrak va metabolik, immunologiya, nevrologiya, onkologiya va gematologiya kabi terapevtik sohalarga qaratilgan. U Leqvio (inclisiran), LDL xolesterinini kamaytirish uchun terapiyani ishlab chiqish, ishlab chiqarish va tijoratlashtirish bo'yicha Alnylam Pharmaceuticals, Inc. bilan litsenziya va hamkorlik shartnomasiga ega. Novartis AG 1996 yilda tashkil etilgan va shtab-kvartirasi Bazel, Shveytsariyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Patrick Horber M.D. | President of International |
| Dr. Robert Kowalski Pharm.D. | Chief People & Organization Officer |
| Dr. Steffen Lang Ph.D. | President of Operations |
| Dr. Vasant Narasimhan M.D. | Chief Executive Officer |
| Mr. Mukul Mehta | Chief Financial Officer |
| Mr. Victor Bulto | President of US |
| Ms. Karen L. Hale | Chief Legal & Compliance Officer |
| Ms. Sloan Simpson |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-18 | 6-K | tm268725d5_6k.htm |
| 2026-01-16 | S-8 POS | tm262520d4_s8pos.htm |
| 2026-01-14 | DFAN14A | tm263179d1_dfan14a.htm |
| 2026-01-12 | DFAN14A | tm262936d1_dfan14a.htm |
| 2025-11-25 | 6-K | f6k_112425.htm |
| 2025-11-20 | 6-K | f6k_112025.htm |
| 2025-11-05 | 6-K | tm2529850d5_6k.htm |
| 2025-10-28 | DFAN14A | tm2529507d4_dfan14a.htm |
| 2025-10-27 | DFAN14A | tm2529507d3_dfan14a.htm |
| 2025-10-22 | SC TO-T/A | tm2527010d10_sctota.htm |
| Global Head of Investor Relations |
| Paul Penepent | Head of Group Financial Reporting and Accounting |